Medical experts discuss the financial impact of early detection in colorectal cancer.
Ryan Haumschild, PharmD, MS, MBA, emphasizes the importance of early detection, tailored interventions, and the associated costs in treating colorectal cancer. He highlights the financial burdens on patients, health care systems, and payers, pointing out the expenses linked to hospitalizations, surgeries, and long-term treatment.
David Fenstermacher, PhD, delves into the economic impact of metastatic colorectal cancer. He mentions that in 2020, approximately $22 billion was spent on colorectal cancer care, making it the second most costly cancer type after female breast cancer. Dr Fenstermacher emphasizes the need to reduce financial toxicity and discusses the high costs of biomarker testing, genetics analysis, and the overall economic burden on both insured and uninsured patients.
Ben George, MD, highlights the importance of early detection and prevention, emphasizing that if patients receive a diagnosis of cancer at a late stage, it results in significant financial and systemic toxicity. Early detection in stages 1 and 2 can lead to a 90% cure rate, underlining the value of identifying high-risk individuals through genetic risk scores.
John L. Marshall, MD, offers a controversial perspective on screening. He argues that the current screening methods are invasive, expensive, and lack the high sensitivity and specificity required for early detection. Dr Marshall questions whether the increased incidence of colorectal cancer from these screenings ultimately leads to more cures, and he calls for a more cost-effective and noninvasive approach to screening.
The discussion revolves around the challenges of early detection and the financial burdens associated with colorectal cancer care, with a focus on seeking innovative ways to enhance screening, reduce financial toxicity, and improve outcomes for patients.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More